Table 2.
OR (95%CI) | p Value | |
---|---|---|
Model 1: Rbinap | ||
Lung primary (vs. other locations) | 0.70 (0.21–2.38) | 0.570 |
SCNEC (vs. NET or LCNEC) | 8.89 (2.26–30.4) | 0.001 |
Rbinap (vs. Rbapp) | 1.70 (0.54–5.37) | 0.368 |
Ki-67 (each additional 1%) | 1 50.97–1.02) | 0.550 |
Model 2: Rb < 150 | ||
Lung primary (vs. other locations) | 0.70 (0.20–2.41) | 0.566 |
SCNEC (vs. NET or LCNEC) | 7.83 (2.25–27.28) | 0.001 |
Rb < 150 (vs. Rb score ≥ 150) | 4.16 (1.11–15.53) | 0.034 |
Ki-67 (each additional 1%) | 0.99 (0.96–1.01) | 0.309 |
Model 3: p16high | ||
Lung primary (vs. other locations) | 0.71 (0.21–2.47) | 0.602 |
SCNEC (vs. NET or LCNEC) | 7.63 (2.19–26.57) | 0.001 |
p16high (vs. p16low) | 1.61 (0.47–5.56) | 0.449 |
Ki-67 (each additional 1%) | 1 (0.97–1.02) | 0.804 |
LCNEC, large-cell neuroendocrine carcinoma; NEN, neuroendocrine neoplasm; NET, neuroendocrine tumor; OR, odds ratio; SCNEC, small-cell neuroendocrine carcinoma.